eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology

Hemolytic Disease of Newborn: Multimedia

Author: Sameer Wagle, MBBS, MD, Consulting Staff, Division of Neonatology, Northwest Medical Center of Washington County
Coauthor(s): Prashant G Deshpande, MD, Attending Pediatrician, Department of Pediatrics, Christ Hospital Medical Center and Hope Children's Hospital, Oak Lawn, Illinois; Chairman, Department of Pediatrics, Palos Community Hospital, Palos Heights, Illinois; Assistant Clinical Professor Of Pediatrics, University Of Illinois at Chicago
Contributor Information and Disclosures

Updated: Oct 15, 2009

Multimedia

Liley curve. This graph illustrates an example of...
(Enlarge Image)
Media file 1: Liley curve. This graph illustrates an example of amniotic fluid spectrophotometric reading of 0.206, which when plotted at 35 weeks' gestation falls into zone 3, indicating severe hemolytic disease.
[ CLOSE WINDOW ]
Liley curve. This graph illustrates an example of...

Liley curve. This graph illustrates an example of amniotic fluid spectrophotometric reading of 0.206, which when plotted at 35 weeks' gestation falls into zone 3, indicating severe hemolytic disease.

Modified Liley curve for gestation of less than 2...
(Enlarge Image)
Media file 2: Modified Liley curve for gestation of less than 24 weeks showing that bilirubin levels in amniotic fluid peak at 23-24 weeks' gestation.
[ CLOSE WINDOW ]
Modified Liley curve for gestation of less than 2...

Modified Liley curve for gestation of less than 24 weeks showing that bilirubin levels in amniotic fluid peak at 23-24 weeks' gestation.

Queenan Curve: Modified Liley curve that shows de...
(Enlarge Image)
Media file 3: Queenan Curve: Modified Liley curve that shows delta-OD 450 values at 14-40 weeks' gestation.
[ CLOSE WINDOW ]
Queenan Curve: Modified Liley curve that shows de...

Queenan Curve: Modified Liley curve that shows delta-OD 450 values at 14-40 weeks' gestation.

Slopes for peak systolic velocity in middle cereb...
(Enlarge Image)
Media file 4: Slopes for peak systolic velocity in middle cerebral artery (MCA) for normal fetuses (dotted line), mildly anemic fetuses (thin line), and severely anemia fetuses (thick line).
[ CLOSE WINDOW ]
Slopes for peak systolic velocity in middle cereb...

Slopes for peak systolic velocity in middle cerebral artery (MCA) for normal fetuses (dotted line), mildly anemic fetuses (thin line), and severely anemia fetuses (thick line).

Management of first affected pregnancy.
(Enlarge Image)
Media file 5: Management of first affected pregnancy.
[ CLOSE WINDOW ]
Management of first affected pregnancy.

Management of first affected pregnancy.

Management of pregnant women with previously affe...
(Enlarge Image)
Media file 6: Management of pregnant women with previously affected fetus.
[ CLOSE WINDOW ]
Management of pregnant women with previously affe...

Management of pregnant women with previously affected fetus.

More on Hemolytic Disease of Newborn

Overview: Hemolytic Disease of Newborn
Differential Diagnoses & Workup: Hemolytic Disease of Newborn
Treatment & Medication: Hemolytic Disease of Newborn
Follow-up: Hemolytic Disease of Newborn
Multimedia: Hemolytic Disease of Newborn
References
[ CLOSE WINDOW ]

References

  1. Bowman JM. Hemolytic disease (erythroblastosis fetalis). In: Creasy RK, Resnik R. Maternal-fetal medicine. 4th edition. Philadelphia: WB Saunders; 1999:736-767.

  2. [Guideline] Snyder EL, Lipton KS. Prevention of hemolyic disease of the newborn due to anti-D Prenatal/perinatal testing and Rh immune globulin administration. American Association of Blood Banks Association Bulletin. 1998;98:1-6.

  3. Van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev. Jan 2003;17(1):31-44. [Medline].

  4. Singleton BK, Green CA, Avent ND, Martin PG, Smart E, Daka A. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood. Jan 1 2000;95(1):12-8. [Medline].

  5. Moise KJ. Hemolytic disease of the fetus and newborn. In: Creasy RK, Resnik R. Maternal-fetal Medicine: Principles and Practice. 6th edition. Philadelphia: WB Saunders; 2008:477-503.

  6. Luchtman-Jones L, Schwartz AL, Wilson DB. The blood and hematopoietic system. In: Fanaroff AA, Martin RJ, eds. Neonatal-Perinatal Medicine-Diseases of the Fetus and Infant. Vol 2. 8th ed. St. Louis, Mo: Mosby; 2006:1287-1356.

  7. Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA. Jun 26 1991;265(24):3270-4. [Medline].

  8. Martin JA, Hamilton BE, Sutton PD et al. Births; final data for 2002. Natl Vital Stat Rep. 2002;52:1-116.

  9. Eder AF. Update on HDFN: new information on long-standing controversies. Immunohematol. 2006;22(4):188-95. [Medline].

  10. Gruslin-giroux A, Moore TR. Erythroblastosis Fetalis. In: Fanaroff AA, Martin RJ. Neonatal-Perinatal Medicine. Vol 1. 8th edition. St. Louis, MO: Mosby-year book Inc; 2006:389-408.

  11. Moise KJ Jr. Red blood cell alloimmunization in Pregnancy. Seminars in Hematology. 2005;42:169-178.

  12. Harkness UF, Spinnato JA. Prevention and management of RhD isoimmunization. Clin Perinatol. Dec 2004;31(4):721-42, vi. [Medline].

  13. Bianchi DW, Avent ND, Costa JM, van der Schoot CE. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time. Obstet Gynecol. 2005;106(4):841-4. [Medline].

  14. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn. 2004;8(1):23-31. [Medline].

  15. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. Jul 2008;112(1):164-76. [Medline].

  16. Liley AW. Liquor amnii analysis in management of pregnancy complicated by rhesus immunization. Am J Obstet Gynecol. 1961;82:1359-71.

  17. Bowman JM, Pollock JM. Amniotic fluid spectrophotometry and early delivery in the management of erythroblastosis fetalis. Pediatr. May 1965;35:815-835. [Medline].

  18. Nicolaides KH, Rodeck CH, Mibashan RS, Kemp JR. Have Liley charts outlived their usefulness?. Am J Obstet Gynecol. Jul 1986;155(1):90-4. [Medline].

  19. Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. Am J Obstet Gynecol. May 1993;168(5):1370-6. [Medline].

  20. Scott F, Chan FY. Assessment of the clinical usefulness of the "Queenan" chart versus the "Liley" chart in predicting severity of rhesus iso-immuinization. Prenat Diagn. (11) 1998;18:1143-48. [Medline].

  21. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. Jul 13 2006;355(2):156-164. [Medline].

  22. Mentzer, WC, Glader BE. Erythrocyte Disorders in Infancy. In: Taeusch HW, Ballard RA eds. Avery's Diseases of the Newborn. 8th Edition. Philadelphia, PA: Elsevier Saunders; 2005:1180-1214.

  23. Koenig JM. Evaluation and treatment of erythroblastosis fetalis in the neonate. In: Christensen R, ed. Hematologic Problems of the Neonate. Philadelphia, Pa: WB Saunders; 2000:185-207.

  24. Vidnes J, Finne H. Immunoreactive insulin in amniotic fluid from Rh-immunized women. Biol Neonate. 1977;31(1-2):1-6. [Medline].

  25. Romano EL, Hughes-Jones NC, Mollison PL. Direct antiglobulin reaction in ABO-haemolytic disease of the newborn. Br Med J. Mar 3 1973;1(852):524-6. [Medline].

  26. Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. Mar 2007;92(2):F83-8. [Medline].

  27. Vaughan JI, Warwick R, Letsky E, et al. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol. Jul 1994;171(1):247-52. [Medline].

  28. Bowman J. The management of hemolytic disease in the fetus and newborn. Semin Perinatol. Feb 1997;21(1):39-44. [Medline].

  29. Segata M, Mari G. Fetal anemia: new technologies. Curr Opin Obstet Gynecol. Apr 2004;16(2):153-8. [Medline].

  30. Zimmerman R, Carpenter RJ, Durig P, et al. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG. Jul 2002;109(7):746-52. [Medline].

  31. ACOG Practice Bulletin No. 75: management of alloimmunization. Obstet Gynecol. Aug 2006;108(2):457-64. [Medline].

  32. Opekes D, seward G, Vandenbussche F, et al. Minimally invasive management of rh alloimmunization: Can amniotic fluid delta OD 450 be replaced by Doppler studies? A prospective study multicenter trial. Am J Obstet Gynecol. 2004;191:S3.

  33. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. Jul 2008;112(1):164-76. [Medline].

  34. Schumacher B, Moise KJ. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol. Jul 1996;88(1):137-50. [Medline].

  35. Trevett TN, Dorman K, Lamvu G, Moise KJ. Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. Feb 2005;192(2):478-82. [Medline].

  36. Moise KJ. Grand Rounds: Rh disease: It's still a threat. Contemporary Ob/Gyn. 2004/05;49:34-48.

  37. Voto LS, Mathet ER, Zapaterio JL, et al. High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease. J Perinat Med. 1997;25(1):85-8. [Medline].

  38. Kriplani A, Singh BM, Mandal K. Fetal intravenous immunoglobulin therapy in Rhesus Hemolytic Disease. Gynecol Obstet Invest. 2007;63:176-180.

  39. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003 Jan;88(1):F6-10. 88(1);2003:F6-10. [Medline].

  40. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics. Jan 2004;113(1 Pt 1):119-23. [Medline].

  41. Madan, A, MacMahon JR, Stevenson DK. Neonatal hyperbilirubinemia. In: Taeusch HW, Ballard RA, eds. Avery's Diseases of The Newborn. 8th ed. Philadelphia, Pa: Elsevier Saunders; 2005:1226-1256.

  42. [Guideline] Maisels MJ, Baltz RD, Bhutani V, et al. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. Jul 2004;114(1):297-316. [Medline].

  43. Martin CR, Cloherty JP. Neonatal Hyperbilirubinemia. In: Cloherty JP, Eichenwald EC, Stark AR. Manual of Neonatal Care. 5th Edition. Philadelphia: Lippincott Williams and Wilkins; 2004:181-212.

  44. Wong RJ, DeSandre GH, Stevenson DK. Neonatal jaundice and liver disease. In: Fanaroff AA, Martin RJ. Neonatal-Perinatal Medicine: Diseases of the fetus and Infant. Vol 2. 7th edition. St. Louis, MO: Mosby-year book Inc; 2002:1419-11466.

  45. Peterec SM. Management of neonatal Rh disease. Clin Perinatol. Sep 1995;22(3):561-92. [Medline].

  46. Hammerman C, Vreman HJ, Kaplan M, Stevenson DK. Intravenous immune globulin in neonatal immune hemolytic disease: does it reduce hemolysis?. Acta Paediatr. Nov 1996;85(11):1351-3. [Medline].

  47. Ovali F, Samanci N, Dagoglu T. Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res. May 1996;39(5):831-4. [Medline].

  48. Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. Jul 2007;120(1):27-32. [Medline].

  49. Hudon L, Moise KJ, Hegemier SE, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol. Oct 1998;179(4):858-63. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

hemolytic disease of the newborn, HDN, Hemolytic disease of fetus and newborn, HDFN, erythroblastosis fetalis, transplacental hemorrhage, fetomaternal hemorrhage, alloimmunization, hemolysis, hyperbilirubinemia, jaundice, kernicterus, nonimmune hydrops fetalis, fetal hydrops, anemia, erythroblasts, placental abruption, spontaneous abortion, therapeutic abortion, toxemia, fetal ascites, pleural effusion, hypoalbuminemia, fetal blood sampling, FBS, hereditary spherocytosis, hereditary elliptocytosis, hereditary pyropoikilocytosis, glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase deficiency, triosephosphate isomerase deficiency, hemorrhages, hypothyroidism, gastrointestinal obstruction, syphilis, cytomegalovirus, CMV, parvovirus

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Sameer Wagle, MBBS, MD, Consulting Staff, Division of Neonatology, Northwest Medical Center of Washington County
Sameer Wagle, MBBS, MD is a member of the following medical societies: American Academy of Pediatrics and American Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Prashant G Deshpande, MD, Attending Pediatrician, Department of Pediatrics, Christ Hospital Medical Center and Hope Children's Hospital, Oak Lawn, Illinois; Chairman, Department of Pediatrics, Palos Community Hospital, Palos Heights, Illinois; Assistant Clinical Professor Of Pediatrics, University Of Illinois at Chicago
Prashant G Deshpande, MD is a member of the following medical societies: American Academy of Pediatrics and American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Oussama Itani, MD, FAAP, FACN, Clinical Associate Professor of Pediatrics and Human Development, Michigan State University; Medical Director, Department of Neonatology, Borgess Medical Center
Oussama Itani, MD, FAAP, FACN is a member of the following medical societies: American Academy of Pediatrics, American College of Nutrition, American College of Physician Executives, and American Heart Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

David A Clark, MD, Chairman, Professor, Department of Pediatrics, Albany Medical College
David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Pediatric Society, Christian Medical & Dental Society, Medical Society of the State of New York, New York Academy of Sciences, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.